Karyopharm Therapeutics (kpti 3 10/15/25)
13F holders, Q3 2025 (September 30)2holders +1
1new positions
0sold out
$0.82avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Karyopharm Therapeutics (kpti 3 10/15/25) in their 13F filings, up 1 from Q2 2025. 1 opened new positions and 0 sold out. The largest holders were Exome Asset Management LLC ($1.6M) and BLB&B Advisors, LLC ($61K).
- Company
- Karyopharm Therapeutics (kpti 3 10/15/25)
- CUSIP
- 48576UAA4
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $61K |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 75,000 shares bought, net +75,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Exome Asset Management LLC | 1.08% | No change | 2,000,000 | $1.6M |
| BLB&B Advisors, LLC | 0.00% | New | 75,000 | $61K |
"% of holder's portfolio" is KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25)'s weight in each manager's 13F, not the share of Karyopharm Therapeutics (kpti 3 10/15/25) the manager owns.